| Expression pattern: |
DN |
| Associated gene: |
FOXP1 |
| Associated microRNA: |
- |
| Biological function: |
Differentially expressed in AML and evaluated as a candidate biomarker for distinguishing AML patients from healthy donor controls; the authors speculated it might relate to FOXP1 transcription. |
| Molecular mechanism: |
The study speculated that circRNA-FOXP1 might promote transcription of its parental gene FOXP1, but did not experimentally validate this mechanism. |
| Biological pathway or process: |
other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; Survival Analysis; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
circ-FOXP1 distinguished AML patients from healthy donor controls, but was not correlated with risk stratification, complete remission, EFS or OS. |
| Description: |
circ-FOXP1 was validated by RT-qPCR as down-regulated in AML BMMCs. It showed diagnostic potential for distinguishing AML patients from healthy controls, and the authors speculated that it might affect transcription of its parental gene FOXP1, but no direct mechanistic validation was provided. |
| Confidence score: |
0.636 |